P
PIQUR Therapeutics
Clinical-stage oncology drugs targeting PI3K/mTOR pathways
About PIQUR Therapeutics
PIQUR Therapeutics AG was a Swiss clinical-stage pharmaceutical company focused on developing anti-cancer drugs by inhibiting the PI3K (phosphoinositide 3-kinase) and mTOR (mammalian target of rapamycin) signaling pathways. The company was established in August 2011 as a spin-off from the University of Basel.
The company was co-founded by Dr. Vladimir Cmiljanovic and his sister, Dr. Natasa Cmiljanovic. Their work on what would become the company's lead drug candidate originated during their Ph.D. studies at the University of Basel. Dr. Vladimir Cmiljanovic, a medicinal chemist and serial entrepreneur, led the company as CEO, securing significant funding and winning accolades such as the Swiss Economic Forum Award in 2015.
PIQUR's primary asset was bimiralisib (also known as PQR309), an oral, brain-penetrant, dual PI3K/mTOR inhibitor. This compound was developed for targeted cancer therapy and showed potential in treating various tumors, including those affecting the brain, due to its ability to cross the blood-brain barrier. The company advanced PQR309 through multiple Phase 1 and Phase 2 clinical trials for advanced solid tumors, lymphomas, and in combination with other drugs for breast cancer. The business model centered on the discovery and clinical development of these proprietary drug candidates, aiming for partnerships and licensing agreements with larger pharmaceutical firms. For instance, PIQUR entered into a collaboration with Pierre Fabre for dermato-oncology.
Over its operational period, PIQUR raised more than CHF 100 million in funding from private investors and venture capital firms like Versant Ventures. Despite its promising research and clinical progress, the company was officially liquidated in 2022. In 2023, Swiss Rockets AG, an incubator co-founded by the Cmiljanovics in 2018, acquired all assets and intellectual property of Piqur. These assets were subsequently transferred to a new entity, Torqur AG, which continues the development of bimiralisib and a pipeline of next-generation PI3K/mTOR inhibitors.
Source: Dealroom company dataNews
Open roles
PIQUR Therapeutics in the Basel ecosystem
The PIQUR Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about PIQUR Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PIQUR Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


